Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Marconi, S; Bonaconsa, M; Scambi, I; Squintani, GM; Rui, W; Turano, E; Ungaro, D; D'Agostino, S; Barbieri, F; Angiari, S; Farinazzo, A; Constantin, G; Del Carro, U; Bonetti, B; Mariotti, R.
Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model.
Neuroscience. 2013; 248: 333-343.
Doi: 10.1016/j.neuroscience.2013.05.034
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Angiari Stefano
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Therapeutic strategies for the fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS) are actually minimally effective on patients' survival and quality of life. Although stem cell therapy has raised great expectations, information on the involved molecular mechanisms is still limited. Here we assessed the efficacy of the systemic administration of adipose-derived mesenchymal stem cells (ASC), a previously untested stem cell population, in superoxide-dismutase 1 (SOD1)-mutant transgenic mice, the animal model of familial ALS. The administration of ASC to SOD1-mutant mice at the clinical onset significantly delayed motor deterioration for 4-6 weeks, as shown by clinical and neurophysiological tests. Neuropathological examination of ASC-treated SOD1-mutant mice at day 100 (i.e. the time of their best motor performance) revealed a higher number of lumbar motorneurons than in phosphate-buffered saline-treated SOD1-mutant mice and a restricted number of undifferentiated green fluorescent protein-labeled ASC in the spinal cord. By examining the spinal cord tissue factors that may prolong neuronal survival, we found a significant up-regulation in levels of glial-derived neurotrophic factor (GDNF) and basic fibroblast growth factor (bFGF) after ASC treatment. Considering that ASC produce bFGF but not GDNF, these findings indicate that ASC may promote neuroprotection either directly and/or by modulating the secretome of local glial cells toward a neuroprotective phenotype. Such neuroprotection resulted in a strong and long-lasting effect on motor performance and encourages the use of ASC in human pathologies, in which current therapies are not able to maintain a satisfying neurological functional status. Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adiposity -
- Amyotrophic Lateral Sclerosis - pathology
- Amyotrophic Lateral Sclerosis - physiopathology
- Amyotrophic Lateral Sclerosis - therapy
- Animals -
- Disease Models, Animal -
- Fibroblast Growth Factor 2 - metabolism
- Glial Cell Line-Derived Neurotrophic Factor - metabolism
- Male -
- Mesenchymal Stem Cell Transplantation - methods
- Mesenchymal Stem Cells - cytology
- Mesenchymal Stem Cells - physiology
- Mice -
- Mice, Transgenic -
- Motor Activity -
- Motor Neurons - cytology
- Motor Neurons - metabolism
- Motor Neurons - physiology
- Neuroprotective Agents -
- Spinal Cord - cytology
- Superoxide Dismutase - genetics
- Superoxide Dismutase-1 -
- Treatment Outcome -
- Up-Regulation -
- Find related publications in this database (Keywords)
- amyotrophic lateral sclerosis
- motorneuron disease
- neurotrophins
- GDNF
- neuroprotection